Read by QxMD icon Read

Cisplatin ototoxicity

Reo Tanoshima, Amna Khan, Agnieszka K Biala, Jessica N Trueman, Britt I Drögemöller, Galen E B Wright, Jafar S Hasbullah, Gabriella S S Groeneweg, Colin J D Ross, Bruce C Carleton
Adverse drug reactions (ADRs) are a major problem in modern medicine, representing up to the fourth-highest cause of mortality. Pharmacogenomic tests are 1 of the most promising methods to tackle the challenge of ADRs. The objective of this study was to analyze the clinical and demographic information of the pan-Canadian active surveillance network, Canadian Pharmacogenomics Network for Drug Safety (CPNDS). Information entered into the database by trained active surveillors between May 15, 2005 and May 9, 2017 was collected and analyzed...
November 19, 2018: Journal of Clinical Pharmacology
P H P Liberman, M V S Goffi-Gomez, C Schultz, P L Jacob, C A A de Paula, E L Sartorato, G T Torrezan, E N Ferreira, D M Carraro
BACKGROUND AND AIM: Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin. MATERIALS AND METHODS: Patients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled...
October 25, 2018: Clinical & Translational Oncology
Margaret S Robertson, Susan S Hayashi, Miranda L Camet, Kathryn Trinkaus, Jennifer Henry, Robert J Hayashi
BACKGROUND: Ototoxicity is a significant complication of cisplatin treatment. Hearing loss can be symmetric or asymmetric, and may decline after therapy. This study examined the risks of asymmetric and late-onset hearing loss (LOHL) in cisplatin-treated pediatric patients with cancer. METHODS: A retrospective review of 993 patients' medical and audiological charts from August 1990 to March 2015 was conducted using stringent criteria to characterize patients with asymmetric hearing loss (AHL) or LOHL...
October 18, 2018: Pediatric Blood & Cancer
Giovanni Giurdanella, Giuseppe Montalbano, Florinda Gennuso, Serena Brancati, Debora Lo Furno, Antonio Augello, Claudio Bucolo, Filippo Drago, Salvatore Salomone
The study of strial pericytes has gained great interest as they are pivotal for the physiology of stria vascularis. To provide an easily accessible in vitro model, here we described a growth medium-based approach to obtain and cultivate primary bovine cochlear pericytes (BCP) from the stria vascularis of explanted bovine cochleae. We obtained high-quality pericytes in 8-10 days with a > 90% purity after the second passage. Immunocytochemical analysis showed a homogeneous population of cells expressing typical pericyte markers, such as neural/glial antigen 2 (NG2), platelet-derived growth factor receptorβ (PDGFRβ), α-smooth muscle actin (α-SMA), and negative for the endothelial marker von Willebrand factor...
March 2019: Journal of Cellular Physiology
Sonia M Rocha Sanchez, Olivia Fuson, Shikha Tarang, Linda Goodman, Umesh Pyakurel, Huizhan Liu, David Z He, Marisa Zallocchi
Hair cell (HC) death is the leading cause of hearing and balance disorders in humans. It can be triggered by multiple insults, including noise, aging, and treatment with certain therapeutic drugs. As society becomes more technologically advanced, the source of noise pollution and the use of drugs with ototoxic side effects are rapidly increasing, posing a threat to our hearing health. Although the underlying mechanism by which ototoxins affect auditory function varies, they share common intracellular byproducts, particularly generation of reactive oxygen species...
October 11, 2018: Scientific Reports
Matthew R Trendowski, Omar El Charif, Paul C Dinh, Lois B Travis, M Eileen Dolan
Effective administration of traditional cytotoxic chemotherapy is often limited by off-target toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent that has potent antineoplastic activity due to its affinity for DNA and other intracellular nucleophiles. Despite its efficacy against many adult-onset and pediatric malignancies, cisplatin elicits multiple off-target toxicities that can not only severely impact a patient's quality of life, but also lead to dose reductions or the selection of alternative therapies that can ultimately affect outcomes...
October 10, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Bapurao Surnar, Nagesh Kolishetti, Uttara Basu, Anis Ahmad, Erik Goka, Brian Marples, David Kolb, Marc E Lippman, Shanta Dhar
Cisplatin is a major chemotherapeutic that continues to have a significant impact in the treatment of more than 50% of all cancers. Since its Food and Drug Administration approval in 1978 for the treatment of advanced ovarian and bladder cancer, this chemotherapeutic has made significant strides and its application has been extended to a large variety of other cancers. However, the vast majority of patients who receive cisplatin therapy often suffer from nephrotoxicity, neurotoxicity, nausea, and ototoxicity...
November 7, 2018: Biochemistry
Mehmet Akif Somdaş, İnayet Güntürk, Esra Balcıoğlu, Deniz Avcı, Cevat Yazıcı, Saim Özdamar
INTRODUCTION: Ototoxicity is a health problem appearing after powerful treatments in serious health conditions. It is sometimes inevitable when treatment of the serious disease is required. Cisplatin is an antineoplastic agent which was investigated previously to reveal increased nitrogen and reactive oxygen radicals that damages hair cells, resulting in ototoxicity. N-acetylcysteine, previously shown to decrease ototoxicity caused by different agents, is known to be a powerful in vitro antioxidant...
September 14, 2018: Brazilian Journal of Otorhinolaryngology
Yasmeen Goyal, Ashwani Koul, Pavitra Ranawat
Cis-diamminedichloroplatinum(II) (cisplatin) (CP) is an important chemotherapeutic agent used in the treatment of several cancers. However, it has several side effects including nephrotoxicity gonadotoxicity, hepatotoxicity, and ototoxicity. In in vitro experiments, antioxidants or reactive oxygen species scavengers have a cytoprotective effect on cells exposed to cisplatin (CP). Ellagic acid (EA) is one such bioactive polyphenol that is abundant in some fruits, nuts, and seeds. Various authors have reported that EA has strong antioxidant and antitumor potential...
September 27, 2018: Molecular and Cellular Biochemistry
Eric C Bielefeld, Alex Markle, J Riley DeBacker, Ryan T Harrison
Cisplatin is a potent chemotherapeutic compound for which ototoxicity is a significant side effect. Cisplatin has shown sensitivity to circadian time, in that cisplatin is most effective as an anti-tumor compound, and least nephrotoxic, when given in the active (dark) period of the light-dark cycle in rodents. The objective of the study was to determine the sensitivity of cisplatin ototoxicity to circadian time. Fifty-seven Fischer 344/NHsd rats were exposed to 12 mg/kg cisplatin by intra-peritoneal injection at one of six time points on a 12 h light-12 h dark cycle: 2, 6, or 10 h after light onset or 2, 6, or 10 h after light offset...
December 2018: Hearing Research
Mengyi Hou, Zhenglan Huang, Sicheng Chen, Hao Wang, Tianyu Feng, Shujuan Yan, Yuxi Su, Guowei Zuo
Cisplatin, as a first-line chemotherapy drug, has been widely applied for therapy of osteosarcoma. However, its application is limited by drug resistance and serious side effects, including nephrotoxicity and ototoxicity. Suberoylanilide hydroxamic acid (SAHA) is a newly developed histone deacetylase (HDAC) inhibitor, which is the first Food and Drug Administration-approved HDAC inhibitor for the treatment of cutaneous manifestations of T-cell lymphoma. However, SAHA as a monotherapy was revealed to be limited, particularly in solid tumors...
October 2018: Oncology Letters
Balamurali Kalyanam, N Sarala, S M Azeem Mohiyuddin, Ravi Diwakar
Background: Cisplatin is one of the anticancer drugs used for head and neck cancers. Although some studies have shown that cisplatin can cause ototoxicity, periodic audiometric assessments have not been extensively studied in the Indian rural population. Hence, this study has been undertaken to evaluate the effects of cisplatin on hearing. Materials and Methods: Fifty-nine patients with squamous cell carcinomas of head and neck, who received cisplatin chemotherapy, were recruited...
July 2018: Journal of Cancer Research and Therapeutics
H Bengu Cobanoglu, Erkan Vuralkan, Abdullah Arslan, Bengusu Mirasoglu, A Savas Toklu
Objectives: Cisplatin is an antineoplastic agent, used in the treatment of different types of malignant neoplasms. Side effects such as ototoxicity, nephrotoxicity, and bone marrow toxicity are the main limitations of its clinical use. The aim of the present study was to evaluate the possible effects of hyperbaric oxygen (HBO) therapy as a protective agent in cisplatin-induced ototoxicity in rats. Methods: A total of 30 adult Wistar rats (60 ears) were divided into five equal groups...
September 8, 2018: Clinical and Experimental Otorhinolaryngology
Alexander A Boucher, Tomoyuki Mizuno, Alexander A Vinks, Stuart L Goldstein, Greg M Tiao, James I Geller
Hepatoblastoma can be associated with chronic kidney disease and genitourinary anomalies. Cisplatin is a key agent for treating hepatoblastoma but renal clearance and toxicity can limit its use in end-stage renal disease. We present pharmacokinetic data and clinical outcomes using cisplatin on hemodialysis for three patients with hepatoblastoma. All patients were initially treated with surgery and adjuvant cisplatin [1.67 mg/kg (2 patients) or 50 mg/m2 (1 patient)]. The patient treated with body surface area-based dosing had higher exposures and ototoxicity...
August 30, 2018: Pediatric Blood & Cancer
Muhammed Sedat Sakat, Korhan Kilic, Fazile Nur Ekinci Akdemir, Serkan Yildirim, Gizem Eser, Ahmet Kiziltunc
INTRODUCTION: Ototoxicity refers to cellular damage or function impairment developing in the inner ear in association with any therapeutic agent or chemical substance, and still represents the principal side-effect restricting the use of cisplatin. OBJECTIVE: The aim of this study was to perform a biochemical, functional and histopathological investigation of the potential protective effect of eugenol against cisplatin-induced ototoxicity. METHODS: The study was performed with 24 female Sprague Dawley rats...
August 7, 2018: Brazilian Journal of Otorhinolaryngology
O L Mironovich, E A Bliznetz, E S Garbaruk, M B Belogurova, N V Subora, S R Varfolomeeva, D Yu Kachanov, T V Shamanskaya, T G Markova, A V Polyakov
Cisplatin and its derivatives are widely used chemotherapeutic agents for the treatment of many cancers, including hepatoblastoma, brain tumors, and germ-cell tumors. This therapy contributed to the dramatic increase in the survival rate. However, its use is restricted by the high incidence of irreversible ototoxicity associated with cisplatin application (in more than 60% of the children receiving it). Some studies have reported that genetic variants of TPMT (rs 12201199), COMT (rs4646316), and ABCC3 (rs 1051640) are conferring increased risk of developing cisplatin-induced hearing loss...
2018: Vestnik Otorinolaringologii
Gabrielle Lui, Naïm Bouazza, Françoise Denoyelle, Marion Moine, Laurence Brugières, Pascal Chastagner, Nadège Corradini, Natacha Entz-Werle, Cécile Vérité, Judith Landmanparker, Hélène Sudour-Bonnange, Marlène Pasquet, Arnauld Verschuur, Cécile Faure-Conter, François Doz, Jean-Marc Tréluyer
Platinum is extensively used in the treatment of several childhood cancers. However, ototoxicity is one of the most notable adverse effects, especially in children. Several studies suggest that genetics may predict its occurrence. Here, polymorphisms associated with platinum-induced ototoxicity were selected from the literature and were investigated in a pediatric population treated with platinum-based agents. In this retrospective study, patients treated with cisplatin and/or carboplatin were screened. The patients with pre- and post-treatment audiogram (Brock criteria) available were included...
July 20, 2018: Oncotarget
L H Braun, K Braun, B Frey, S M Wolpert, H Löwenheim, D Zips, S Welz
BACKGROUND: Cochlea sparing can reduce late ototoxicity in head and neck cancer patients treated with cisplatin-based radiochemotherapy. In this situation, a mean cochlear dose (MCD) constraint of 10 Gy has been suggested by others based on the dose-effect relationship of clinical data. We aimed to investigate whether this is feasible for primary and postoperative radiochemotherapy in locoregionally advanced tumors without compromising target coverage. PATIENTS AND METHODS: Ten patients treated with definitive and ten patients treated with adjuvant intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy were investigated...
December 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Meng Wei, Xiaojun Yuan
Cisplatin is the principal chemotherapeutic agent and also tremendously increases the survival for pediatric patients with neuroblastoma or hepatoblastoma. With the extended overall survival period, clinical medical workers and parents gradually attach more attention to the late effect of chemotherapy of these children. The purpose of this study is to analyze the incidence and risk factors of cisplatin-based hearing loss. We retrospectively collected the archives of cisplatin-based chemotherapy and audiometric evaluation from 2005 through 2017 at Xinhua Hospital...
August 8, 2018: Journal of Pediatric Hematology/oncology
Robert A Hazlitt, Tal Teitz, Justine D Bonga, Jie Fang, Shiyong Diao, Luigi Iconaru, Lei Yang, Asli N Goktug, Duane G Currier, Taosheng Chen, Zoran Rankovic, Jaeki Min, Jian Zuo
There are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin...
September 13, 2018: Journal of Medicinal Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"